












































Pharmaceuticals —





Pipeline Overview



December 13, 2022 – Investor Relations



Pharmaceuticals – Pipeline Overview¹ (as of Dec 13, 2022)

Phase 0 ²	Phase I	Phase II	Phase III
DGKalpha Inh (BAY 2862789)  ●	Elimusertib (ATR Inhibitor) (BAY 1895344)  ●	Regorafenib (combi Nivolumab) (BAY 734506)  ○	Copanlisib (PI3K Inhibitor) (BAY 806946)  ○
PSMA TAC (BAY 3546828)  ●	AhR Inhibitor (BAY 2416964)  ●	Asundexian (FXIa Inhibitor) (BAY 2433334)  ●	Darolutamide (AR Inhibitor) (BAY 1841788)  ○
PSMA SMOL TAC (BAY 3563254)  ●	mEGFR Inhibitor (BAY 2927088)  ●	Runcaciguat (sGC Activator) (BAY 1101042)  ●	Finerenone (MR Antagonist) (BAY 948862)  ○
VVD NRF2 Inh (BAY 3605349)  ●	227Th-Trastuzumab corixetan (HER2 TTC) (BAY 2701439)  ●	BDKRB1 Receptor Antagonist (BAY 2395840)  ●	Vericiguat (sGC Stimulator) (BAY1021189)  ○
VVD STAT3 Inh (BAY 3630914)  ●	DGKzeta Inhibitor (BAY 2965501)  ●	Gadoquatrane (High Relaxivity Contrast Agent) (BAY 1747846)  ●	Asundexian (FXIa Inhibitor) (BAY 2433334)  ●
SEMA 3^a (BAY 3401016)  ●	CCR8 Ab (BAY 3375968)  ●	Adrenomedullin Pegol (PEG-ADM) (BAY 1097761)  ●	Elinzanetant (Neurokinin-1,3 Rec Antagonist) (BAY 3427080)  ●
LGMD2i Gene Therapy (LION-101)  ●	Congestive Heart Failure Gene Therapy (NAN-101)  ●		Aflibercept 8MG (BAY 865321)  ○
Next Generation Liver MRI (BAY 3393081)  ●	sGC Activator (BAY 3283142)  ●		Darolutamide (AR Inhibitor) / ADT with Chemotherapy  ○
	Anti-a2AP (BAY 3018250)  ●		Aflibercept (VEGF inhibitor)  ○
	P2X4 Antagonist (BAY 2328065)  ●		
	BDKRB1 Receptor Antagonist (BAY 2395840)  ●		
	Zabedoseritib (IRAK4 Inhibitor) (BAY 1834845)  ●		
	sGC Activator (BAY 1211163)  ●		
	Parkinson's Disease Cell Therapy (BRT-DA-01)  ●		
	Parkinson's Disease Gene Therapy (AAV2-GDNF-PD)  ●		
	Multiple System Atrophy Gene Therapy (AAV2-GDNF-MSA)  ●		
	Pompe Disease Gene Therapy (ACTUS-101)  ●		
	Huntington's Disease Gene Therapy (BV-101)  ●		

-  Oncology
-  Cardiovascular Diseases
-  Women's Health
-  Others

-  New therapeutic entity
-  Life cycle management

-  Antibody
-  Biologic
-  Cell Therapy
-  Contrast Agent
-  Gene Therapy
-  Radiotherapy
-  Small Molecule

¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit ² Pre-clinical selected assets on path to IND ³ Conducted by Merck & Co ⁴ Conducted by Regeneron Pharmaceuticals



Pharmaceuticals – Pipeline Details Phase III¹ (as of Dec 13, 2022)

Therapeutic Area	Candidate medication	Modality	Compound Origin	Indication	Ct.gov Identifier	Estimated/actual primary completion	Status
Oncology	Copanlisib (PI3K Inhibitor)		Bayer	Non-Hodgkin Lymphoma (<i>CHRONOS-4</i>)	NCT02626455	Q1 2023	Study ongoing
	Darolutamide (AR Inhibitor)		Orion	Prostate Cancer (mHSPC) (<i>ARANOTE</i>)	NCT04736199	Q1 2024	Study ongoing
				Adjuvant Prostate Cancer (<i>DASL-HiCaP</i>)	NCT04136353	Q1 2028	Study ongoing
Cardiovascular Diseases	Finerenone (MR Antagonist)		Bayer	Heart Failure (HFmr/pEF) (<i>FINEARTS-HF</i>)	NCT04435626	Q3 2024	Study ongoing
				Non-diabetic CKD (<i>FIND-CKD</i>)	NCT05047263	Q1 2026	Study ongoing
	Vericiguat (sGC Stimulator)		Bayer	Heart Failure (HFrEF) (<i>VICTOR³</i>)	NCT05093933	Q1 2025	Study ongoing
	Asundexian (FXIa Inhibitor)		Bayer	Stroke Prevention in Atrial Fibrillation (<i>OCEANIC-AF</i>)	NCT05643573	Q3 2025	Study ongoing
Women's Health	Elinzanetant (Neurokinin-1,3 Rec Antagonist)		KaNdy	Vasomotor Symptoms (<i>OASIS-1, OASIS-2, OASIS-3, OASIS-4</i>)	NCT05042362 NCT05099159 NCT05030584 NCT05587296	Q2 2023 Q2 2023 Q1 2023 Q1 2024	Studies ongoing
Others	Aflibercept 8MG		Regeneron	Diabetic Macular Edema (DME) (<i>PHOTON⁴</i>)	NCT04429503	Q2 2022	Primary completion date achieved. Data presented at AAO in Oct. 2022
				Neovasc. Age-rel. Macular Degen. (nAMD) (<i>PULSAR</i>)	NCT04423718	Q3 2022	

¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit ³ Conducted by Merck & Co ⁴ Conducted by Regeneron Pharmaceuticals

Antibody Biologic Cell Therapy Contrast Agent Gene Therapy Radiotherapy Small Molecule



Pharmaceuticals – Pipeline Details Phase II¹ (as of Dec 13, 2022)

Therapeutic Area	Candidate medication	Modality	Compound Origin	Indication	Ct.gov Identifier	Estimated/actual primary completion	Status
Oncology	Regorafenib (combi Nivolumab) (BAY 734506)		Bayer	Solid tumors (recurrent or metastatic)	NCT04704154	Q1 2023	Study ongoing
Cardiovascular Diseases	Asundexian (FXIa Inhibitor) (BAY 2433334)		Bayer	2° Stroke Prevention (PACIFIC-STROKE) Major Adverse Cardiac Events Prevention (PACIFIC-AMI)	NCT04304508 NCT04304534	Q1 2022 Q1 2022	Studies completed; data presented at ESC in Aug. 2022
	Runcaciguat (sGC Activator) (BAY 1101042)		Bayer	Chronic Kidney Disease (CKD) (CONCORD)	NCT04507061	Q1 2022	
Others	BDKRB1 Receptor Antagonist (BAY 2395840)		Bayer/Evotec	Neuropathic Pain (BRADINP)	NCT05219812	Q4 2022	Study ongoing
	Gadoquatrane (High Relaxivity Contrast Agent, HRCA) (BAY 1747846)		Bayer	Magnetic Resonance Imaging (HRCA-PAT)	NCT04307186	Q4 2022	Study ongoing
	Runcaciguat (sGC Activator) (BAY 1101042)		Bayer	Non-prolif. Diabetic Retinopathy (NPDR) (NEON-NPDR)	NCT04722991	Q4 2023	Study ongoing
	Adrenomedullin Pegol (PEG-ADM) (BAY 1097761)		Bayer	Acute Resp. Distress Syn. (ARDS) (SEAL)	NCT04417036	Q4 2024	Study ongoing

¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit

Antibody
 Biologic
 Cell Therapy
 Contrast Agent
 Gene Therapy
 Radiotherapy
 Small Molecule



Pharmaceuticals – Pipeline Details Phase I¹ (as of Dec 13, 2022)

Therapeutic Area	Candidate medication	Modality	Compound Origin	Indication	Ct.gov Identifier	Estimated/actual primary completion	Status
Oncology	Elimusertib (ATR Inhibitor) (BAY 1895344)		Bayer	Advanced solid tumors, Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma	NCT03188965 NCT04095273 NCT04267939	Q4 2022 / Q1 2025	Studies ongoing
	AhR Inhibitor (BAY 2416964)		Bayer/DKFZ	Advanced solid tumors	NCT04069026 NCT04999202	Q1 2025 / Q2 2025	Studies ongoing
	mEGFR Inhibitor (BAY 2927088)		Bayer/Broad Institute	Advanced Non-small Cell Lung Cancer with EGFR Mutation and/or HER2 Mutation	NCT05099172	Q4 2025	Study ongoing
	²²⁷ Th-Trastuzumab corixetan (HER2 TTC) (BAY 2701439)		Bayer	Cancers with HER2 Expression	NCT04147819	Q3 2026	Study ongoing
	DGKzeta Inhibitor (BAY 2965501)		Bayer/DKFZ	Cancer	NCT05614102	Q3 2026	Study ongoing
	CCR8 Ab (BAY 3375968)		Bayer	Advanced solid tumors	NCT05537740	Q4 2026	Study ongoing
Cardiovascular Diseases	Congestive Heart Failure Gene Therapy (NAN-101)		AskBio	Congestive Heart Failure	NCT04179643		Phase I study and planning activities for subsequent phases ongoing
	sGC Activator (BAY 3283142)		Bayer	Chronic Kidney Disease (CKD)	NCT05491642	Q1 2023	Study ongoing
	Anti-a2AP (BAY 3018250)		Bayer	Acute Ischemic Stroke; Pulmonary Embolism		Q2 2023	Study planned
Women's Health	P2X4 Antagonist (BAY 2328065)		Bayer	Endometriosis	NCT03427788 NCT04027192 NCT04851483	Q4 2018 / Q3 2020 / Q4 2021	Phase II decision expected in HY1 2023
	BDKRB1 Receptor Antagonist (BAY 2395840)		Bayer/Evotec	Endometriosis	NCT05517746	Q4 2020	Phase II decision expected in HY1 2023
Other	Zabedoseritib (IRAK4 Inhibitor) (BAY 1834845)		Bayer	Atopic Dermatitis		Q4 2017 / Q3 2020	Studies completed. Phase II decision taken for Atopic Dermatitis
	sGC Activator (BAY 1211163)		Bayer	Acute Respiratory Distress Syndrome	NCT04609943	Q2 2023	Study ongoing
	Parkinson's Disease Cell Therapy (BRT-DA-01)		BlueRock	Parkinson's Disease	NCT04802733	Q2 2023	Study ongoing
	Parkinson's Disease Gene Therapy (AAV2-GDNF-PD)		AskBio	Parkinson's Disease	NCT04167540	Q4 2023	Study ongoing
	Multiple System Atrophy Gene Therapy (AAV2-GDNF-MSA)		AskBio	Multiple System Atrophy	NCT04680065	Q1 2024	Study recruiting
	Pompe Disease Gene Therapy (ACTUS-101)		AskBio	Pompe Disease	NCT03533673	Q2 2025	Study ongoing
	Huntington's Disease Gene Therapy (BV-101)		AskBio	Huntington's Disease	NCT05541627	Q4 2025	Study recruiting

¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit





Pharmaceuticals – Pipeline Details Oncology¹ (as of Dec 13, 2022)

Candidate medication	Indication	Modality	Compound Origin	Phase 0 ²	Phase I	Phase II	Phase III	Ct.gov Identifier	Estimated/actual primary completion	Status
Copanlisib (PI3K Inhibitor) (BAY 806946)	Non-Hodgkin Lymphoma (CHRONOS-4)		Bayer					NCT02626455	Q1 2023	Study ongoing
Darolutamide (AR Inhibitor) (BAY 1841788)	Prostate Cancer (mHSPC) (ARANOTE)		Orion					NCT04736199	Q1 2024	Study ongoing
	Adjuvant Prostate Cancer (DASL-HiCaP)							NCT04136353	Q1 2028	Study ongoing
Regorafenib (combi Nivolumab) (BAY 734506)	Solid tumors (recurrent or metastatic)		Bayer					NCT04704154	Q1 2023	Study ongoing
Elimusertib (ATR Inhibitor) (BAY 1895344)	Advanced solid tumors, Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma		Bayer					NCT03188965 NCT04095273 NCT04267939	Q4 2022 Q1 2023 Q1 2025	Studies ongoing
AhR Inhibitor (BAY 2416964)	Advanced solid tumors		Bayer/DKFZ					NCT04069026 NCT04999202	Q1 2025 Q2 2025	Studies ongoing
mEGFR Inhibitor (BAY 2927088)	Advanced Non-small Cell Lung Cancer with EGFR Mutation and/or HER2 Mutation		Bayer/Broad Institute					NCT05099172	Q4 2025	Study ongoing
²²⁷ Th-Trastuzumab corixetan (HER2 TTC) (BAY 2701439)	Cancers with HER2 Expression		Bayer					NCT04147819	Q3 2026	Study ongoing
DGKzeta Inhibitor (BAY 2965501)	Cancer		Bayer/DKFZ					NCT05614102	Q3 2026	Study ongoing
CCR8 Ab (BAY 3375968)	Advanced solid tumors		Bayer					NCT05537740	Q4 2026	Study ongoing
DGKalpha Inh (BAY 2862789)	Cancer		Bayer/DKFZ							
PSMA TAC (BAY 3546828)	Advanced Prostate Cancer		Lantheus (prev. Progenics)							
PSMA SMOL TAC (BAY 3563254)	Advanced Prostate Cancer		Noria Therapeutics/PSMA Therapeutics							
VVD NRF2 Inh (BAY 3605349)	Cancer		Vividion							
VVD STAT3 Inh (BAY 3630914)	Cancer		Vividion							

¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit ² Pre-clinical selected assets on path to IND

Antibody
 Biologic
 Cell Therapy
 Contrast Agent
 Gene Therapy
 Radiotherapy
 Small Molecule



Pharmaceuticals – Pipeline Details Cardio. Diseases¹ (as of Dec 13, 2022)

Candidate medication	Indication	Modality	Compound Origin	Phase 0 ²	Phase I	Phase II	Phase III	Ct.gov Identifier	Estimated/actual primary completion	Status
Finerenone (MR Antagonist) (BAY 948862)	Heart Failure (HFmr/pEF) (FINEARTS-HF)		Bayer					NCT04435626	Q3 2024	Study ongoing
	Non-diabetic CKD (FIND-CKD)				NCT05047263	Q1 2026	Study ongoing			
Vericiguat (sGC Stimulator) (BAY1021189)	Heart Failure (HFREF) (VICTOR ³)		Bayer					NCT05093933	Q1 2025	Study ongoing
Asundexian (FXIa Inhibitor) (BAY 2433334)	Stroke Prevention in Atrial Fibrillation (OCEANIC-AF)		Bayer					NCT05643573	Q3 2025	Study ongoing
	2° Stroke Prevention (OCEANIC-STROKE)				NCT04304508	Q1 2022	Phase II studies completed; data presented at ESC in Aug. 2022			
	Major Adverse Cardiac Events Prevention (PACIFIC-AMI)				NCT04304534	Q1 2022				
Runcaciguat (sGC Activator) (BAY 1101042)	Chronic Kidney Disease (CKD) (CONCORD)		Bayer					NCT04507061	Q1 2022	Study completed; detailed evaluation ongoing
Congestive Heart Failure Gene Therapy (NAN-101)	Congestive Heart Failure		AskBio					NCT04179643		Phase I study and planning activities for subsequent phases ongoing
sGC Activator (BAY 3283142)	Chronic Kidney Disease (CKD)		Bayer					NCT05491642	Q1 2023	Study ongoing
Anti-α2AP (BAY 3018250)	Acute Ischemic Stroke; Pulmonary Embolism		Bayer						Q2 2023	Study planned
SEMA 3^a (BAY 3401016)	Acute Kidney Injury, Alport Syndrome		Bayer/Evotec							

¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit ² Pre-clinical selected assets on path to IND ³ Conducted by Merck & Co



Pharmaceuticals – Pipeline Details Women’s Health¹ (as of Dec 13, 2022)

Candidate medication	Indication	Modality	Compound Origin	Phase 0 ²	Phase I	Phase II	Phase III	Ct.gov Identifier	Estimated/actual primary completion	Status
Elinzanetant (Neurokinin-1,3 Rec Antagonist) (BAY 3427080)	Vasomotor Symptoms (OASIS-1, OASIS-2, OASIS-3, OASIS-4)		KaNDy					NCT05042362 NCT05099159 NCT05030584 NCT05587296	Q2 2023 Q2 2023 Q1 2023 Q1 2024	Studies ongoing
P2X4 Antagonist (BAY 2328065)	Endometriosis		Bayer					NCT03427788 NCT04027192 NCT04851483	Q4 2018 Q3 2020 Q4 2021	Studies completed; Phase II decision expected in HY1 2023
BDKRB1 Receptor Antagonist (BAY 2395840)	Endometriosis		Bayer/Evotec					NCT05517746	Q4 2020	Phase II decision expected in HY1 2023

¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit ² Pre-clinical selected assets on path to IND





Pharmaceuticals – Pipeline Details Other Ther. Areas¹ (as of Dec 13, 2022)

Candidate medication	Indication	Modality	Compound Origin	Phase 0 ²	Phase I	Phase II	Phase III	Ct.gov Identifier	Estimated/actual primary completion	Status
Aflibercept 8MG (BAY 865321)	Diabetic Macular Edema (DME) (PHOTON ⁴)		Regeneron					NCT04429503	Q2 2022	Primary completion date achieved. Data presented at AAO in Oct. 2022
	Neovasc. Age-rel. Macular Degen. (nAMD) (PULSAR)							NCT04423718	Q3 2022	
BDKRB1 Receptor Antagonist (BAY 2395840)	Neuropathic Pain (BRADINP)		Bayer/Evotec					NCT05219812	Q4 2022	Study ongoing
Gadoquatrane (High Relaxivity Contrast Agent (HRCA) (BAY 1747846)	Magnetic Resonance Imaging (HRCA-PAT)		Bayer					NCT04307186	Q4 2022	Study ongoing
Runcaciguat (sGC Activator) (BAY 1101042)	Non-prolif. Diabetic Retinopathy (NPDR) (NEON-NPDR)		Bayer					NCT04722991	Q4 2023	Study ongoing
Adrenomedullin Pegol (PEG-ADM) (BAY 1097761)	Acute Resp. Distress Syn. (ARDS) (SEAL)		Bayer					NCT04417036	Q4 2024	Study ongoing
Zabedoseritb (IRAK4 Inhibitor) (BAY 1834845)	Atopic Dermatitis		Bayer							Studies completed. Phase II decision taken for Atopic Dermatitis
sGC Activator (BAY 1211163)	Acute Respiratory Distress Syndrome		Bayer					NCT04609943	Q2 2023	Study ongoing
Parkinson's Disease Cell Therapy (BRT-DA-01)	Parkinson's Disease		BlueRock					NCT04802733	Q2 2023	Study ongoing
Parkinson's Disease Gene Therapy (AAV2-GDNF-PD)	Parkinson's Disease		AskBio					NCT04167540	Q4 2023	Study ongoing
Multiple System Atrophy Gene Therapy (AAV2-GDNF-MSA)	Multiple System Atrophy		AskBio					NCT04680065	Q1 2024	Study recruiting
Pompe Disease Gene Therapy (ACTUS-101)	Pompe Disease		AskBio					NCT03533673	Q2 2025	Study ongoing
Huntington's Disease Gene Therapy (BV-101)	Huntington's Disease		AskBio					NCT05541627	Q4 2025	Study recruiting
LGMD2i Gene Therapy (LION-101)	Limb-Girdle Muscular Dystrophy 2i		AskBio							
Next Generation Liver MRI (BAY 3393081)	Contrast Media		Bayer							

¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit ² Pre-clinical selected assets on path to IND ⁴ Conducted by Regeneron Pharmaceuticals

Antibody
 Biologic
 Cell Therapy
 Contrast Agent
 Gene Therapy
 Radiotherapy
 Small Molecule